WeChat· 多肽圈·· 10 hours agoPickScore71
Lilly's EloraTZP Combination Cut Weight 23.3% at 48 Weeks in Phase II, Phase III AMPLIFY-1/2 Launched
In brief
Lilly reported Phase II data for its combination obesity drug EloraTZP at the EASD congress, showing 23.3% weight loss at 48 weeks. The same day, the company launched AMPLIFY-1 (n=2115, adults with obesity but no diabetes) and AMPLIFY-2 (n=1000).
Why it matters
EloraTZP showed 23.3% weight loss at 48 weeks in Phase II and is compared head-to-head with tirzepatide, eloralintide, and placebo to isolate the combination's added benefit.
Source: WeChat · mp.weixin.qq.com